Remote-Arbeiten in der Forschung

Clippings
June 1, 2021

PHARMAustria sprach mit Priv.-Doz. Dr. Ghazaleh Gouya Lechner, Vorstandsmitglied der Österreichischen Gesellschaft für Pharmazeutische Medizin (GPMed), über die Situation der medizinischen Forschung in Pandemiezeiten, das vermehrte Remote-Arbeiten sowie die zukünftige Rolle von Artificial Intelligence bei klinischen Studien. (s.44)

pa-2021-02-lr_pub Download

Schedule Your Expert Hour

Get INSIGHTS into the strategies you need for a successful clinical trial!

Share This Post

More To Explore

Avoid CTIS submission mistakes when applying for clinical trials in drug development

General

Most Common CTIS Submission Mistakes

Learn the most common CTIS submission mistakes in Part I and Part II documents. Submit your EU CTIS without delays.

Ghazaleh Gouya 21.05.2026

Early stage companies need to know when to interact with the European Medicines Agency (EMA)

General

How Early-Stage Biotech Companies Should First Engage with ITF EMA

Early-stage biotech companies often contact the EMA too late. Learn when and how to request an EMA Innovation Task Force (ITF) meeting, how it differs from Scientific Advice, and what to prepare before your first ITF EMA engagement.

Ghazaleh Gouya 21.05.2026